Edgemont Pharmaceuticals Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 4

Edgemont Pharmaceuticals General Information

Description

Developer of novel drugs intended for the treatment of psychiatric disorders. The company's novel drug formulations and therapies in the field of neuroscience helps in the treatment of major depressive disorder, bulimia nervosa, obsessive-compulsive disorder and panic disorder, enabling the neurological patients to resist their depression and anxiety problems.

Contact Information

Website
www.edgemontpharma.com
Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • 1250 Capital of Texas
  • Highway South, Building 3, Suite 400
  • Austin, TX 78746
  • United States
Primary Industry
Biotechnology
Acquirer
Alvogen Group
Vertical(s)
Life Sciences
Corporate Office
  • 1250 Capital of Texas
  • Highway South, Building 3, Suite 400
  • Austin, TX 78746
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Edgemont Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Edgemont Pharmaceuticals‘s full profile, request access.

Request a free trial

Edgemont Pharmaceuticals Patents

  • 11

    Total Documents Applications and Grants

  • Total Patents Families

  • 5

    Granted

  • Pending

  • Expiring in next 12 mo

Edgemont Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20150190345-A1 Controlled release formulations of lorazepam Inactive 08-Jan-2014
JP-2017019880-A Sustained release formulations of lorazepam Inactive 09-Jan-2013
EP-2943186-A1 Controlled release formulations of lorazepam Inactive 09-Jan-2013
AU-2014205440-A1 Sustained release formulations of lorazepam Active 09-Jan-2013
CA-2897313-A1 Controlled release formulations of lorazepam Inactive 09-Jan-2013 A61K9/2031
To view Edgemont Pharmaceuticals’s complete patent history, request access »

Edgemont Pharmaceuticals Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Edgemont Pharmaceuticals‘s full profile, request access.

Request a free trial

Edgemont Pharmaceuticals FAQs

  • When was Edgemont Pharmaceuticals founded?

    Edgemont Pharmaceuticals was founded in 2006.

  • Where is Edgemont Pharmaceuticals headquartered?

    Edgemont Pharmaceuticals is headquartered in Austin, TX.

  • What industry is Edgemont Pharmaceuticals in?

    Edgemont Pharmaceuticals’s primary industry is Biotechnology.

  • Is Edgemont Pharmaceuticals a private or public company?

    Edgemont Pharmaceuticals is a Private company.

  • What is Edgemont Pharmaceuticals’s current revenue?

    The current revenue for Edgemont Pharmaceuticals is .

  • How much funding has Edgemont Pharmaceuticals raised over time?

    Edgemont Pharmaceuticals has raised $14.8M.

  • Who are Edgemont Pharmaceuticals’s investors?

    Spindletop Capital has invested in Edgemont Pharmaceuticals.

  • Who acquired Edgemont Pharmaceuticals?

    Edgemont Pharmaceuticals was acquired by Alvogen Group.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »